Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 1,951 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the sale, the director directly owned 11,048 shares in the company, valued at $1,449,055.68. The trade was a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $130.19, for a total value of $15,102.04.
• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $95.96, for a total value of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total value of $9,840.28.

Guardant Health Stock Performance

Shares of GH stock opened at $130.83 on Wednesday. The firm has a market cap of $17.35 billion, a P/E ratio of -38.59 and a beta of 1.61. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $135.00. The business’s 50 day moving average price is $109.11 and its 200-day moving average price is $103.22.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Erste Asset Management GmbH raised its stake in shares of Guardant Health by 10.4% in the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after purchasing an additional 66,617 shares during the last quarter. World Investment Advisors purchased a new stake in shares of Guardant Health during the fourth quarter valued at $1,664,000. Segall Bryant & Hamill LLC boosted its position in shares of Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after buying an additional 111,822 shares during the last quarter. TD Asset Management Inc increased its holdings in Guardant Health by 16.1% in the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after buying an additional 26,210 shares in the last quarter. Finally, Algert Global LLC increased its holdings in Guardant Health by 169.1% in the 3rd quarter. Algert Global LLC now owns 120,114 shares of the company’s stock worth $7,505,000 after buying an additional 75,474 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Guggenheim cut shares of Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. Wolfe Research began coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Barclays increased their price target on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.